News
-
-
-
PRESS RELEASE
Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19
Bioxytran, Inc. announces positive results from Phase 1b/2a clinical study evaluating oral ProLectin-M in COVID-19 patients, showing earlier viral clearance, clinical improvement, and safety